Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Wetzel, J; Pilz, S; Grübler, MR; Fahrleitner-Pammer, A; Dimai, HP; von Lewinski, D; Kolesnik, E; Perl, S; Trummer, C; Schwetz, V; Meinitzer, A; Belyavskiy, E; Völkl, J; Catena, C; Brandenburg, V; März, W; Pieske, B; Brussee, H; Tomaschitz, A; Verheyen, ND.
Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism: The EPATH trial.
J Clin Hypertens (Greenwich). 2017; 19(11):1173-1180 Doi: 10.1111/jch.13064 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Verheyen Nicolas Dominik
Wetzel Julia
Co-Autor*innen der Med Uni Graz
Belyavskiy Evgeny
Brussee Helmut
Dimai Hans Peter
Fahrleitner-Pammer Astrid
Grübler Martin
Kolesnik Ewald
März Winfried
Meinitzer Andreas
Perl Sabine
Pieske Burkert Mathias
Pilz Stefan
Theiler-Schwetz Verena
Tomaschitz Andreas
Trummer Christian
von Lewinski Dirk
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Patients with primary hyperparathyroidism are at increased risk for high blood pressure, vascular stiffening, and left ventricular hypertrophy, but previous studies have failed to demonstrate the direct associations with circulating parathyroid hormone (PTH) levels. The authors investigated cross-sectional relationships between PTH and 24-hour pulse wave velocity, nocturnal systolic blood pressure, and left ventricular mass index in patients with primary hyperparathyroidism who were treatment-naive with cinacalcet, renin-angiotensin-aldosterone-system inhibitors, and thiazide or loop diuretics. In 76 patients, mean±SD of pulse wave velocity, nocturnal systolic blood pressure, and left ventricular mass index values were 9.3±1.8 m/s, 116.6±17.0 mm Hg, and 92.8±23.0 g/m². In multivariate linear regression analyses with adjustment for potentially confounding parameters, PTH was independently associated with nocturnal systolic blood pressure (adjusted ß coefficient=.284, P=.040), mean 24-hour pulse wave velocity (ß=.199, P=.001), and left ventricular mass index (ß=.252, P=.025). PTH may promote vascular and cardiac remodeling in primary hyperparathyroidism. Interventional trials are needed to test the antihypertensive and cardioprotective effects of PTH-inhibitory treatment strategies. ©2017 Wiley Periodicals, Inc.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Antihypertensive Agents - pharmacology
Blood Pressure - physiology
Blood Pressure Monitoring, Ambulatory - methods
Cardiotonic Agents - pharmacology
Cardiovascular Diseases - blood
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - etiology
Cardiovascular Diseases - prevention & control
Echocardiography - methods
Female -
Heart Ventricles - pathology
Humans -
Hyperparathyroidism, Primary - blood
Hyperparathyroidism, Primary - complications
Hyperparathyroidism, Primary - diagnosis
Hyperparathyroidism, Primary - physiopathology
Hypertension - blood
Hypertension - diagnosis
Hypertension - drug therapy
Hypertension - physiopathology
Male -
Middle Aged -
Organ Size -
Parathyroid Hormone - blood
Pulse Wave Analysis - methods

Find related publications in this database (Keywords)
ambulatory blood pressure monitoring
blood pressure
left ventricular mass
parathyroid hormone
primary hyperparathyroidism
pulse wave velocity
© Med Uni Graz Impressum